8-K: Kura Oncology Reports Positive Q1 2025 Results Driven by Ziftomenib Progress

Kura Oncology announces Q1 2025 financial results, highlighted by the NDA submission for ziftomenib and a $45 million milestone payment.

Summary

• Kura Oncology reported its first quarter 2025 financial results and provided a corporate update on May 1, 2025.
• A New Drug Application (NDA) for ziftomenib was submitted to the FDA for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation.
• The FDA has a 60-day filing review period, with a decision expected in the second quarter of 2025.
• The NDA submission triggered a $45 million milestone payment from Kyowa Kirin under their collaboration agreement.
• First patients were dosed in a Phase 1 trial of ziftomenib plus imatinib in GIST.
• Collaboration revenue for Q1 2025 was $14.1 million, compared to no revenue in Q1 2024.
• Research and development expenses for Q1 2025 were $56.0 million, up from $36.3 million in Q1 2024.
• General and administrative expenses for Q1 2025 were $22.8 million, compared to $18.2 million for Q1 2024.
• The net loss for Q1 2025 was $57.4 million, compared to a net loss of $49.5 million for Q1 2024.
• As of March 31, 2025, Kura had $658.2 million in cash, cash equivalents, and short-term investments, which pro forma including the milestone payment is $703.2 million.
• The company believes its cash will fund operations into 2027 and support the ziftomenib AML program through commercialization in the frontline combination setting.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the NDA submission, milestone payment, and strong cash position, but tempered by increased expenses and net loss.

Positives

• The NDA submission for ziftomenib represents a significant milestone for Kura Oncology.
• The $45 million milestone payment strengthens Kura's financial position.
• The initiation of the Phase 1 trial of ziftomenib plus imatinib in GIST expands the potential applications of ziftomenib.
• The company's cash position is strong, providing runway into 2027.
• Collaboration revenue increased significantly compared to the previous year.

Negatives

• The net loss for Q1 2025 increased compared to Q1 2024.
• Research and development expenses increased significantly compared to the previous year.
• General and administrative expenses increased compared to the previous year.

Risks

• The FDA may not approve the NDA for ziftomenib.
• Clinical trials may not be successful.
• The collaboration with Kyowa Kirin may not be successful.
• The company may need to raise additional capital in the future.

Future Outlook

Kura Oncology believes its current cash, cash equivalents, and short-term investments will be sufficient to fund its current operating expenses into 2027 and, combined with anticipated collaboration funding under the Kyowa Agreement, should support its ziftomenib AML program through commercialization in the frontline combination setting.

Management Comments

• In the first quarter of 2025, we achieved a significant milestone with the submission of our first NDA for ziftomenib, said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
• We are committed to working with FDA to support its review and are strategically advancing our pre-commercial activities to prepare for potential approval for the treatment of adult patients with relapsed or refractory NPM1-mutant AML.
• Beyond the monotherapy setting, we look forward to sharing data on the combination of ziftomenib with intensive and non-intensive standards of care, while gearing up for two Phase 3 studies in the frontline setting.
• With a strong pipeline, multiple clinical data readouts expected this year, and a solid financial foundation, we are well-positioned to drive progress across our programs.

Industry Context

Kura Oncology's progress with ziftomenib in AML addresses a significant unmet need in patients with NPM1 mutations. The collaboration with Kyowa Kirin highlights the growing trend of partnerships in the biopharmaceutical industry to develop and commercialize novel therapies. The focus on precision medicine and targeted therapies aligns with the broader industry shift towards personalized cancer treatments.

Comparison to Industry Standards

• Kura Oncology's NDA submission for ziftomenib puts them in competition with other companies developing therapies for AML, such as Agios Pharmaceuticals (Tibsovo) and Servier (IDHIFA), which target IDH1/2 mutations.
• The $330 million upfront payment and potential $375 million in near-term milestone payments from Kyowa Kirin are comparable to other significant collaboration agreements in the oncology space, such as the deal between Relay Therapeutics and Genentech for $400 million upfront and potential milestones exceeding $1 billion.
• The company's cash runway into 2027 is relatively strong compared to other clinical-stage biopharmaceutical companies, providing them with financial flexibility to advance their pipeline.

Stakeholder Impact

• Shareholders: The NDA submission and strong cash position are positive for shareholders.
• Employees: Continued progress in clinical trials and financial stability provide job security.
• Patients: Potential approval of ziftomenib could provide a new treatment option for AML patients with NPM1 mutations.
• Kyowa Kirin: The collaboration continues to be mutually beneficial.

Next Steps

• FDA review of the NDA for ziftomenib.
• Presentation of data from the KOMET-001 Phase 1b/2 trial at ASCO and EHA in Q2 2025.
• Presentation of preliminary clinical data from the KOMET-007 Phase 1b expansion cohort evaluating ziftomenib with intensive chemotherapy (7+3) in the frontline setting at EHA in Q2 2025.
• Presentation of preliminary clinical data from the KOMET-007 Phase 1b expansion cohort evaluating ziftomenib with venetoclax and azacitidine in the frontline setting at a medical meeting in the second half of 2025.
• Initiation of two independent Phase 3 registration-enabling trials in 1L intensive (KOMET-017-IC) and non-intensive (KOMET-017-NIC) AML in the second half of 2025.
• Nomination of a development candidate for next-generation menin inhibitor program in diabetes in mid-2025.
• Initiation of one or more FIT-001 expansion cohorts of KO-2806 and cabozantinib in patients with advanced renal cell carcinoma in the second half of 2025.
• Presentation of data from the FIT-001 Phase 1 trial evaluating KO-2806 and cabozantinib in patients with renal cell carcinoma in the second half of 2025.
• Presentation of data from the FIT-001 Phase 1 monotherapy dose escalation of KO-2806 in patients with RAS mutations in the second half of 2025.
• Presentation of data from the KURRENT-HN trial evaluating tipifarnib and alpelisib in PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC) in the second half of 2025.

Key Dates

Keywords

ziftomenib, AML, Kura Oncology, NDA, Kyowa Kirin, KOMET-001, KOMET-015, KO-2806, GIST, NPM1 mutation, clinical trials, financial results